This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Is Keryx Biopharma (KERX) Up 4% Since Last Earnings Report?
by Zacks Equity Research
Keryx Biopharma (KERX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Keryx (KERX) Looks Good: Stock Adds 7.2% in Session
by Zacks Equity Research
Keryx (KERX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Keryx's (KERX) Loss Narrower Than Expected in Q3, Sales Lag
by Zacks Equity Research
Keryx's (KERX) sole marketed product generates sales of $26.6 million in the third quarter, up 96% from the year-ago quarter.
Keryx's (KERX) Loss Wider Than Expected in Q2, Sales Lag
by Zacks Equity Research
Keryx (KERX) posts wider-than-expected loss in Q2. Moreover, revenues miss the mark.
Keryx (KERX) Loss Wider Than Expected in Q2, Sales Miss
by Zacks Equity Research
Keryx Biopharmaceuticals (KERX) reports wider-than-expected loss in Q2, revenues too miss estimates.
What's in Store for ImmunoGen (IMGN) This Earnings Season?
by Zacks Equity Research
ImmunoGen's (IMGN) considerable progress with lead pipeline candidate, mirvetuximab soravtansine, is expected to drive investor interest in the second-quarter earnings call.
Is a Beat in Store for Keryx (KERX) This Earnings Season?
by Zacks Equity Research
Keryx (KERX) is likely to provide updates on the merger with Akebia along with the updates on Auryxia at the second quarter call.
5 Biotech Stocks Well Poised to Beat Q2 Earnings Estimates
by Zacks Equity Research
Biotech industry experiences a turnaround in June. Here are five stocks which are expected to beat expectation in Q2.
Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More
by Zacks Equity Research
Key headlines in the biotech sector last week include Gilead getting positive CHMP opinion, Keryx plunging on merger news while Celgene and Amgen came out with pipeline updates.
Keryx (KERX) Inks Merger Deal With Akebia, Shares Fall
by Zacks Equity Research
Keryx Biopharmaceuticals (KERX) enters into a definitive merger agreement with Akebia Therapeutics, Inc. under which the companies will combine in an all-stock merger.
Why is Keryx (KERX) Down 2.7% Since its Last Earnings Report?
by Zacks Equity Research
Keryx (KERX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Keryx (KERX) Loss Narrower than Expected in Q1, Sales Beat
by Zacks Equity Research
Keryx's (KERX) loss in the first quarter of 2018 was narrower than expected while sales beat estimates. The company remains encouraged by the performance of its lead drug Auryxia.
Keryx (KERX) Posts Narrower Than Expected Q4 Loss, Sales Beat
by Madhu Goel
Keryx's first-quarter 2018 loss was narrower-than-expected and sales beat estimates.
What's in Store for Endocyte (ECYT) This Earnings Season?
by Zacks Equity Research
Endocyte (ECYT) is expected to provide updates on pipeline candidates when it reports first-quarter 2018 results on May 9 after the market closes.
5 Biotech Stocks Set to Beat Estimates This Earnings Season
by Zacks Equity Research
Given the large number of biotech firms, the task of selecting stocks with possibilities to beat estimates could appear daunting. We pick five biotech stocks likely to deliver an earnings surprise.
BioDelivery Sciences (BDSI) Q1 Earnings: What to Expect?
by Zacks Equity Research
Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).
Is a Beat in Store for Epizyme (EPZM) This Earnings Season?
by Zacks Equity Research
Epizyme (EPZM) is expected to provide updates on pipeline candidates when it reports Q1 results on May 8.
Puma Biotech (PBYI) to Report Q1 Earnings: What to Expect?
by Zacks Equity Research
On the Q1 call, investor focus will be on sales of Puma Biotechnology's (PBYI) only marketed product, Nerlynx and updates on other label expansion studies on the drug.
What's in the Offing for Keryx (KERX) This Earnings Season?
by Zacks Equity Research
Keryx Biopharmaceuticals, Inc. (KERX) is expected to report first-quarter 2018 results on May 3, before the market opens and is expected to provide updates on its lead drug Auryxia.
Options Traders Expect Huge Moves in Keryx (KERX) Stock
by Zacks Equity Research
Investors in Keryx (KERX) need to pay close attention to the stock based on moves in the options market lately.
Is the Options Market Predicting a Spike in Keryx (KERX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Keryx (KERX) stock based on the movements in the options market lately.
Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down
by Zacks Equity Research
Keryx (KERX) reports wider-than-expected loss in Q4. However, sales surpassed estimates.
Keryx (KERX) Posts Wider Q4 Loss, Sales Beat, Shares Down
by Zacks Equity Research
Keryx posted wider than expected loss but beat revenues in the fourth quarter of 2017.
Keryx (KERX) Warming Up to Q4 Earnings: What's in Store?
by Zacks Equity Research
Keryx (KERX) will provide updates on lead drug Auryxia when it reports Q4 results on Feb 7.
Implied Volatility Surging for Keryx Biopharmaceuticals (KERX) Stock Options
by Zacks Equity Research
Investors in Keryx Biopharmaceuticals (KERX) need to pay close attention to the stock based on moves in the options market lately.